Full Press Release Details
TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its presentation at the 42ndAnnual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website athttp://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
About RegeneronRegeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its proprietaryVelociSuite®technologies, such asVelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about Regeneron, please visitwww.regeneron.comor follow Regeneron onLinkedIn.
Contact Information:Investor RelationsRyan Crowe914.847.8790ryan.crowe@regeneron.comCorporate CommunicationsChristina Chan914.847.8827christina.chan@regeneron.com